Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | VHL N78K |
Therapy | Belzutifan |
Indication/Tumor Type | clear cell renal cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
VHL N78K | clear cell renal cell carcinoma | predicted - sensitive | Belzutifan | Case Reports/Case Series | Actionable | In a clinical case study, a patient with metastatic clear cell renal cell carcinoma harboring VHL N78K responded to treatment with Welireg (belzutifan) as a second-line therapy (PMID: 38344974). | 38344974 |
PubMed Id | Reference Title | Details |
---|---|---|
(38344974) | Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation. | Full reference... |